News & Videos - ROSETTA GENOMICS

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / May 18, 2018 / Rosetta Genomics Ltd. (the "Company") (NASDAQ: ROSG) announced today that on May 18, 2018, it received a decision letter from NASDAQ Stock Market ("Nasdaq") following a hearing that was held on May 17, 2018, informing the Company that the Nasdaq Hearing Panel has determined to delist the shares of the Company from the Nasdaq Stock Market and will suspend trading in those shares effective at the open of business on Tuesday, May...

PHILADELPHIA, PAand REHOVOT, ISRAEL / ACCESSWIRE / May 7, 2018 / Rosetta Genomics Ltd. (the "Company") (NASDAQ: ROSG) announced today that on May 2, 2018, it received a "delinquency" delisting notice from NASDAQ Stock Market ("Nasdaq"). The Company has not yet filed its Form 20-F as required pursuant to Nasdaq's Listing Rule 5250(c)(2) for the period ended December 31, 2017.On May 1, 2018, the Company filed a Form 12b-25 stating that, "…the Company does not believe it will be able to file its...

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 26, 2018 / Rosetta Genomics Ltd. (the "Company") (NASDAQ: ROSG) today announced that its shareholders approved a proposed merger with a subsidiary of Genoptix, Inc. ("Genoptix") at an extraordinary general meeting of shareholders. The completion of the merger will be on or about May 27, 2018, subject to satisfaction of customary closing conditions. Israeli law requires a period of 30 days after shareholder approval for a merger to be...

- Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix - If Shareholders Do Not Approve the Merger, Outstanding Ordinary Shares Likely Will Cease to Have Any Value PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 17, 2018 / Rosetta Genomics Ltd. (the ''Company'') (NASDAQ: ROSG) today announced that the extraordinary general meeting of shareholders of that was summoned for April 17, 2018, has been adjourned to Thursday, April 26, 2018 at 10:00 AM (PT) in...

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 10, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announced that Kenneth Berlin will resign as President and CEO effective April 18, 2018 to pursue other opportunities. Mr. Berlin will assist management in a smooth transition with ongoing projects. Brian Markison, Chairman of the Board of Rosetta...

- If Shareholders Do Not Approve the Merger, Outstanding Ordinary Shares Likely Will Cease to Have Any Value - Price Per Ordinary Share Increased to an Estimated $0.42 - $0.50 - This is a New Shareholder Meeting and All Shareholders of Record as of March 20, 2018 Need to Vote Again Regardless of Whether They Voted at the Previous Extraordinary Meeting of Shareholders Held in February 2018 PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 10, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG):...

- If Shareholders do not Approve the Merger, Outstanding Ordinary Shares Likely Will Cease to Have Any Value - This is a New Shareholder Meeting and all Shareholders of Record as of March 20, 2018 Need to Vote Again Regardless of Whether They Voted at the Previous Extraordinary Meeting of Shareholders Held in February 2018 PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / April 5, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG) urges all its shareholders to vote FOR the proposed merger of Rosetta...

Genoptix Will Have Exclusive Distribution Rights in the U.S. and Non-exclusive Rights in Most Geographies Outside the U.S. CARLSBAD, CA, PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / March 13, 2018 / Genoptix, Inc., a leading oncology diagnostic laboratory, and Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, jointly announce that they have entered into an exclusive...

Previously announced meeting date of April 6, 2018, for its extraordinary general meeting of shareholders, has been cancelled and rescheduled for April 17, 2018 New record date for shareholder meeting to approve the merger is March 20, 2018 and Rosetta Genomics strongly urges shareholders to vote for new transaction as its cash position is insufficient to fund operations beyond a short period of time PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / March 12, 2018 / Rosetta Genomics Ltd....

-First step in the process of Genoptix acquiring all of Rosetta Genomics -Next step is the completion of a merger for $8 million in cash pursuant to which value to Rosetta Genomics' equity holders is preliminarily estimated to be $0.40 - $0.45 per ordinary share, after deductions for debt, warrant termination payments, fees, expenses and other items -Record date for shareholder meeting to approve the merger is March 9, 2018 and Rosetta Genomics strongly urges shareholders to vote for new...

- Value to Rosetta Genomics' Equity Holders is Preliminarily Estimated to be $0.40 - $0.45 Per Ordinary Share, After Deductions for Debt, Warrant Termination Payments, Fees, Expenses and Other Items - Rosetta Genomics Strongly Urges Shareholders to Vote for New Transaction as its Cash Position is Insufficient to Fund Operations Beyond a Short Period of Time CARLSBAD, CA, PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / February 27, 2018 / Genoptix, Inc., a leading oncology diagnostic...

Although shares voted were more than 2-to-1 in favor of the merger, the proposal failed to secure a majority of shares outstanding Company considering alternative options with Genoptix LAKE FOREST, CA; PHILADELPHIA, PA; and REHOVOT, ISRAEL / ACCESSWIRE / February 23, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG) ("Rosetta" or "the Company"), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces results from...

Shares voted to date are running 3-to-1 in favor of the merger Emphasizes that shareholders as of December 27, 2017, regardless of whether or not they still hold their shares, are entitled to vote This shareholders meeting cannot be adjourned any further CARLSBAD, CA, PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / February 16, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information...

The value to Rosetta Genomics' equity holders is preliminarily estimated to be $0.60 per ordinary share, after deductions for debt, warrant termination payments, fees, expenses and other items CARLSBAD, CA / PHILADELPHIA, PA / REHOVOT, ISRAEL / ACCESSWIRE / December 15, 2017 / Genoptix, Inc., a leading oncology diagnostic laboratory, and Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to...

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / November 30, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that on November 28, 2017, the Company received a notification letter from The NASDAQ Stock Market ("NASDAQ") notifying the Company that it is not in compliance with the NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule"). The letter indicated...

Continued ramp in samples processed and record commercial collections put RosettaGX Reveal on $4 million annual run rate Independent clinical data in support of the competitive performance of the Reveal assay in classifying indeterminate thyroid nodules were presented at the American Society of Cytopathology Annual Scientific Meeting PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / November 20, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment...

Receives Eighth Patent Related to Classifying Indeterminate Thyroid Nodules with Several Additional Patent Applications in Process PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / November 13, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that it has expanded its global intellectual property portfolio related to classifying indeterminate thyroid...

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / November 8, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG) ("Rosetta" or "the Company"), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that on October 24, 2017, the Company received a notification letter from the NASDAQ Stock Market indicating that the Company's stockholders' equity as reported in the Company's Report on Form 6-K as filed with the...

Data Demonstrate RosettaGX Reveal to have Substantially Higher Specificity than Afirma at Classifying Benign Nodules, with the Potential to Reduce Substantially More Unnecessary Surgeries PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / October 23, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announced favorable data from an independently-conducted study...

Receives Seventh Patent Related to Detecting Thyroid Cancer with Several Additional Patent Applications in Process PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / October 17, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that it has expanded its global patent estate related to classifying indeterminate thyroid nodules (ITN), with a new patent...